Cite

    Wasserman, R. et al. (n.d.). Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability. Immunotherapy. pp. 1175-1186. [Online].